b'Dr Dannielle Cox-Pridmore Dr Dannielle Cox-Pridmore is a Senior Research Associate at the University of East Anglia. Dr Cox-Pridmore recently completed the ICURe Engage programme as an Entrepreneurial Lead for potential spin-out RhosynBio. The company offers a novel chemical-free physical surface resistant to bacterial adhesion and biofilm formation. Dr Cox-Pridmore and RhosynBio were recently shortlisted for the University of East Anglia (UEA) Innovation and Impact Awards in the category of Outstanding Commercial Use of Research. The team has also been selected to join the Impulse 2025 cohort with a fully funded fellowship from the Henry Royce Institute. This opportunity will enable the team to further develop RhosynBio and enhance their entrepreneurial skills alongside a dynamic community of innovators.Dr Cox-Pridmore at the UEA Innovation Dr Joe Parkerand Impact Awards.In January 2025, Dr Joe Parker secured a place on the Innovate UK ICURe Explore research commercialisation programme. Dr Parkers technology focuses on developing digital and physical automation to model and profile industrial and agricultural biofilms. Following an intense three months of training and criss-crossing Europe performing market validation and commercial discovery, the project was reviewed by a panel of biotech entrepreneurs and investors, who recommended Dr Parker and team create a standalone spin-out company. Multiple clients from SMEs to large multinational corporates have already signed letters of intent. Building on this momentum, Dr Kam Pooni, Dr Laura Powel, Dr Parker successfully led his team into the ICURe Exploit as future Dr Joe Parker and Professor Jeremy Webb.CEO of a new company. Explore team members, Dr Kam Pooni (Glyconics Ltd) and Professor Jeremy Webb (NBIC Southampton), will be joined in the next 12 months by other key talent as the team spin-out and continue to develop their unique biofilm consultancy, troubleshooting and validation service for additional clients in agtech and food processing, manufacturing, marine, and water sectors.Dr Ashraf Zarkan, Dr David Summers and Dr Jehangir CamaUniversity of Cambridge spin-out, BioTryp Therapeutics, was co-founded by Dr Ashraf Zarkan, Dr David Summers, and Dr Jehangir Cama. The team are developing novel orally-administered antibiofilm therapies to revolutionise how we treat bacterial infections, providing a much-needed alternative to traditional antibiotics. BioTryps antibiofilm treatment will have a significant indirect value by releasing resources in healthcare, in addition to the direct benefit for patients suffering with Urinary Tract Infections (UTI)s. Since completing the Biofilms ICURe Sprint in 2022, the company has made significant progress. It has been operational for over a year, has raised more than 300,000 in non-dilutive investment as part of its pre-seed round,Dr Ashraf Zarkan at the #21toWatch hired two research scientists, and secured over 400,000 in grants.Awards in Cambridge.In November 2024, BioTryp were one of the three winners in the Startups category at the Santander X Global Challenge/Innovation in Healthcare Awards, which aims to support healthcare systems adapt at the pace of the technological revolution society is experiencing. In March 2025, BioTryp was recognised as one of the Top 7 Companies in the Cofinitive #21toWatch Awards, which highlight exceptional individuals, groundbreaking companies and pioneering innovations from across the East of England. In May 2025, the company reached an inflexion point and is now raising a 2m seed round. 23'